Moxifloxacin HCl , ≥99% , 186826-86-8

Synonym(s):
12-8039;1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride;Avalox;BAY12-8039;Moxifloxacin hydrochloride

CAS NO.：186826-86-8

Empirical Formula: C21H25ClFN3O4

Molecular Weight: 437.892

MDL number: MFCD00949117

EINECS: 641-756-7

PRODUCT Properties

• Melting point: Slightly yellow to yellow crystalline powder, mp 324-325°
• alpha: 25D -256° (c = 0.5 in water)
• Boiling point: 636℃
• RTECS: VB1983750
• Flash point: >110°(230°F)
• storage temp.: 2-8°C
• solubility: H2O: soluble5mg/mL, clear (warmed)
• form: powder
• color: white to beige
• Water Solubility: Sparingly soluble in water. Soluble in DMSO
• BRN: 8377447
• InChIKey: IDIIJJHBXUESQI-DFIJPDEKSA-N
• SMILES: N1(C2CC2)C2=C(C=C(F)C(N3C[C@]4([H])CCCN[C@]4([H])C3)=C2OC)C(=O)C(C(O)=O)=C1.[H]Cl |&1:12,18,r|

Description and Uses

Moxifioxacin hydrochlodde is one of the two new fluoroquinolonecarboxylic acid antibiotics introduced in 1999 for the treatment of respiratory tract infections such as community-acquired pneumonia, acute exacerbations of bronchitis or acute sinusitis. Moxifloxacin can be synthesized through a 12 step sequence from the classical 4-quinolone-3-carboxylic acid template. Some advantages of Moxifloxacin over Ciprofloxacin, another of Bayer's launched quinolones, have been shown, i.e. an enhanced activity against Gram-positive bacteria (Streptococcus pneumoniae, Clostndium pneumoniae), a favorable pharmacokinetic profile (good tissue penetration and plasma concentrations above MICs) and a lack of phototoxicity (UVA irradiation).

Moxifloxacin Hydrochloride is an antibacterial agent that inhibits the activities of Topo II (DNA gyrase) and topoisomerase IV.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H319-H412
• Precautionary statements: P264-P270-P273-P280-P301+P312-P305+P351+P338
• WGK Germany: 2
• HazardClass: IRRITANT